Journal article
Polycomb repressive complex 2 (PRC2) suppresses Eμ-myc lymphoma
SCW Lee, B Phipson, CD Hyland, HS Leong, RS Allan, A Lun, DJ Hilton, SL Nutt, ME Blewitt, GK Smyth, WS Alexander, IJ Majewski
Blood | AMER SOC HEMATOLOGY | Published : 2013
Abstract
Deregulation of polycomb group complexes polycomb repressive complex 1 (PRC1) and 2 (PRC2) is associated with human cancers. Although inactivating mutations in PRC2-encoding genes EZH2, EED, and SUZ12 are present in T-cell acute lymphoblastic leukemia and in myeloid malignancies, gain-of-function mutations in EZH2 are frequently observed in B-cell lymphoma, implying disease-dependent effects of individual mutations. We show that, in contrast to PRC1, PRC2 is a tumor suppressor in Eμ-myc lymphomagenesis, because disease onset was accelerated by heterozygosity for Suz12 or by short hairpin RNA-mediated knockdown of Suz12 or Ezh2. Accelerated lymphomagenesis was associated with increased accumu..
View full abstractGrants
Awarded by Australian Research Council
Funding Acknowledgements
This work was supported by program grants (1016647 and 575500), a project grant (1011663), National Health and Medical Research Council (NHMRC) fellowships (to W. S. A., I.J.M., M. E. B., D.J.H., and G. K. S.), fellowships from the Australia Research Council (to M. E. B. and S.L.N.), a NHMRC-Institut National de la Sante et de la Recherche Medicale Postdoctoral Training fellowship (to R. S. A.), Australian postgraduate awards (to S. C. W. L., B. P., H. S. L., and A. L.), Independent Research Institutes Infrastructure Support Scheme grant 361646 from the NHRMC, the Australian Cancer Research Fund, and a Victorian State Government Operational Infrastructure Support grant.